| Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial T Powles, M Kockx, A Rodriguez-Vida, I Duran, SJ Crabb, ... Nature medicine 25 (11), 1706-1714, 2019 | 527 | 2019 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 514 | 2021 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 442 | 2020 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 145 | 2022 |
| Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment L Muinelo-Romay, M Vieito, A Abalo, M Alonso Nocelo, F Barón, U Anido, ... Cancers 6 (1), 153-165, 2014 | 125 | 2014 |
| Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder B Szabados, M Kockx, ZJ Assaf, PJ van Dam, A Rodriguez-Vida, I Duran, ... European Urology 82 (2), 212-222, 2022 | 107 | 2022 |
| A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). T Powles, A Rodriguez-Vida, I Duran, SJ Crabb, MS Van Der Heijden, ... Journal of Clinical Oncology 36 (15_suppl), 4506-4506, 2018 | 102 | 2018 |
| The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials A Carretero-González, D Lora, I Martin Sobrino, I Saez Sanz, MT Bourlon, ... Cancers 12 (7), 1945, 2020 | 69 | 2020 |
| High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion L Muinelo-Romay, E Colas, J Barbazan, L Alonso-Alconada, ... Molecular cancer therapeutics 10 (8), 1357-1366, 2011 | 65 | 2011 |
| Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience MCA Manrique, JM Martínez, JG González, FJA Afonso, ML Quintela, ... Translational lung cancer research 7 (3), 404, 2018 | 64 | 2018 |
| Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. T Powles, JE Gschwend, Y Loriot, J Bellmunt, L Geczi, C Vulsteke, ... Journal of Clinical Oncology 35 (15_suppl), TPS4590-TPS4590, 2017 | 52 | 2017 |
| Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line … J García-Donas, A Font, B Pérez-Valderrama, JA Virizuela, MÁ Climent, ... The Lancet Oncology 18 (5), 681a, 2017 | 52 | 2017 |
| X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients MJ Lamas, G Duran, A Gomez, E Balboa, U Anido, B Bernardez, ... International Journal of Radiation Oncology* Biology* Physics 82 (1), 138-144, 2012 | 49 | 2012 |
| Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study J Ruiz-Bañobre, A Molina-Díaz, O Fernández-Calvo, N Fernández-Núñez, ... ESMO open 6 (2), 100090, 2021 | 40 | 2021 |
| Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma MJ Méndez-Vidal, Á Molina, U Anido, I Chirivella, O Etxaniz, ... BMC Pharmacology and Toxicology 19, 1-12, 2018 | 36 | 2018 |
| Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone … C De La Piedra, A Alcaraz, J Bellmunt, C Meseguer, A Gómez-Caamano, ... British journal of cancer 108 (12), 2565-2572, 2013 | 36 | 2013 |
| Prospective observational study of pazopanib in patients with advanced renal cell carcinoma (PRINCIPAL study) M Schmidinger, A Bamias, G Procopio, R Hawkins, AR Sanchez, ... The Oncologist 24 (4), 491-497, 2019 | 35 | 2019 |
| A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer J Barbazán, M Vieito, A Abalo, L Alonso‐Alconada, L Muinelo‐Romay, ... Journal of cellular and molecular medicine 16 (10), 2342-2349, 2012 | 32 | 2012 |
| Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG … MÁ Climent, B Pérez-Valderrama, B Mellado, EMF Parra, OF Calvo, ... European Journal of Cancer 87, 30-37, 2017 | 28 | 2017 |
| Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. J Ruiz‐Bañobre, I Abdulkader, U Anido, L León, R López‐López, ... Apmis 125 (3), 2017 | 28 | 2017 |
